General Director of the Emirates Drug Authority: A New Era of Sustainable Pharmaceutical Leadership
The Emirates Drug Authority is preparing to enter a new phase characterized by sustainable pharmaceutical leadership. The organization’s future strategies and directions reflect a holistic vision that balances innovation with responsible practices in the pharmaceutical sector. Dr. Fatima Al Kaabi, the General Director of the authority, sheds light on ambitious plans through an in-depth dialogue that addresses recent developments and future achievements.
Integrated Strategy to Support Leadership
Dr. Al Kaabi emphasized that what has been achieved in the past period is the result of a clear institutional vision. The priority is to build a regulatory system capable of keeping pace with rapid transformations in the pharmaceutical sector by updating frameworks and enhancing the integration between innovation and governance. Al Kaabi states, “We have adopted an advanced approach to developing the regulatory work system and improving procedural efficiency,” which enhances decision-making capabilities and increases the sector’s flexibility. The upcoming phase will seek to deepen this integration and complete the implementation of the authority’s strategy through 2026, focusing on effective partnerships that support the acceleration of innovation and sector competitiveness.
Enhancing Partnerships for Innovation
Dr. Al Kaabi clarified that one of the primary goals is to build strong partnerships with government entities and the private sector to ensure integration between healthcare and pharmaceutical manufacturing. She mentioned, “This integration enhances the readiness of the UAE and solidifies its competitive position.” The UAE’s initiatives in this area align with the future vision of wise leadership that focuses on achieving health and pharmaceutical security as part of national objectives.
Embracing Innovations and New Treatments
In discussing innovative treatments, Al Kaabi pointed to notable achievements, including the approval of a range of advanced therapies through a sophisticated regulatory system. A total of 49 innovative pharmaceutical products were registered in 2025, approved under fast-track registration pathways. The drug “Rilzabrutinib,” approved as the world’s first innovative oral treatment for immune thrombocytopenia, exemplifies the UAE’s ability to lead in this field, making the country the first in the world to approve this treatment.
Sustainability in the Pharmaceutical Sector and Environmental Trends
The authority is moving towards enhancing sustainability in the pharmaceutical sector in line with national environmental goals. Al Kaabi states, “We strive to adopt environmentally friendly practices in the pharmaceutical sector,” noting that the authority contributes to supporting sustainable manufacturing and promotes efficient resource use. The program is also working on formulating strategies that support innovation in areas such as pharmaceutical waste management and the circular economy.
Dr. Fatima Al Kaabi, through a comprehensive vision, aspires to establish the UAE as a leading destination in healthcare and pharmaceuticals. This vision reflects a new phase characterized by sustainable pharmaceutical leadership that aligns with the nation’s goals. Continuing efforts to achieve this objective highlight that the future of the pharmaceutical industry in the UAE is linked to ongoing collaboration and strategic partnerships, reflecting a commitment to quality of life and public health.